CA
NZ
UK
AU
IND
US
Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on therapies addressing central nervous system disorders, announced operational and financial results for the second quarter of fiscal 2026. The update included financial performance details alongside progress on the United States commercialization of EXXUA, an FDA-approved …
Protagonist Therapeutics (NASDAQ:PTGX) is a clinical-stage biopharmaceutical company focused on developing orally administered peptide-based therapies for immune-mediated and other serious diseases. The company applies its proprietary Peptide 2.0 platform to design molecules targeting G protein–coupled receptors and cytokine receptors, aiming to provide oral alternatives …
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) reported that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) indicated a negative trend vote on its Marketing Authorization Application (MAA) for trofinetide, intended for the treatment of Rett syndrome. The feedback follows the recent …
Shares of XBiotech Inc. (NASDAQ:XBIT) traded above their 50-day moving average during the January 30 session, touching an intraday high of USD 2.56. The stock’s 50-day average stood at USD 2.49, while the 200-day moving average was higher at USD 2.67. Despite the intraday …
STAAR Surgical (NASDAQ:STAA) saw its price objective reduced by Jefferies Financial Group, which lowered its target to USD 21.50 from USD 28.00. Despite the cut, the firm reiterated a buy-equivalent rating, suggesting continued confidence in the company’s longer-term fundamentals even as near-term valuation assumptions …
Belite Bio, Inc (NASDAQ:BLTE), a clinical-stage biotechnology company, announced the completion of patient enrollment in its Phase 2/3 DRAGON II clinical trial for tinlarebant, a treatment under investigation for Stargardt disease type 1 (STGD1). The study enrolled 60 adolescent subjects, including 15 participants from …
UnitedHealth Group Incorporated (NYSE:UNH) saw its shares decline steeply in pre-market trading on January 27 after reporting weakerearningsand issuingrevenueguidance for fiscal year 2026 that fell below the prior year’s level.
Shares of Rapt Therapeutics (NASDAQ:RAPT) climbed 64% on Tuesday to close at USD 57.57, following the announcement that the immunology-focused biotechnology company had agreed to be acquired by British pharmaceutical group GSK (NYSE: GSK). Under the terms of the agreement, GSK will acquire Rapt …
Shares of ImmunityBio Inc. (NASDAQ:IBRX) closed Thursday’s session at USD 3.95, marking a30.79% gain for the day. The move followed the company’s release of preliminary full-year 2025 results, which outlined a substantial increase in revenue from its bladder cancer therapy, Anktiva. Over the past …
Shares ofImmunityBio, Inc. (NASDAQ:IBRX)were recently the subject of updated analyst commentary afterD. Boral Capitalreiterated its stock rating in a research note issued to investors. The brokerage maintained a price objective ofUSD 24.00, reflecting its outlook on the biotechnology company following recent developments.
Please wait processing your request...